Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.42 - $18.40
Previous CloseN/A
Volume16.79K
Average Volume (3M)146.54K
Market Cap
$311.98M
Enterprise Value$185.82M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-2.48
Next Earnings
Mar 17, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding50,976,677
10 Day Avg. Volume79,896
30 Day Avg. Volume146,543
Standard Deviation0.32
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$22.75Price Target Upside261.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Market PotentialENGN believes the BCG-unresponsive NMIBC market will grow significantly, potentially increasing from $2 billion to $20 billion, with detalimogene being a first-option in community urology offices.
Product Efficacy And AdoptionDetalimogene has a good chance of being widely adopted in community urologist practices due to its ease of use, administration, tolerability, safety, and efficacy.
Bears Say
Competitive LandscapeEase of use and safety are key considerations, and some patients are choosing Adstiladrin over gemcitabine+docetaxel due to its very good tolerability and convenient dosing, which could bode well for detalimogene's ease of use value proposition.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $4.42 and its highest was $18.40 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $311.98M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Mar 17, 2025 which is in 22 days.
How were enGene Holdings’s earnings last quarter?
Currently, no data Available
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings does not currently pay dividends.
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.38.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 50,976,677 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
---
enGene Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.75 (261.69% Upside)
$22.75 (261.69% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 550.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Company Description
enGene Holdings
Forbion European Acquisition Corp is a blank check company.
---
ENGN Stock 12 Month Forecast
Average Price Target
$22.75
▲(261.69% Upside)
Technical Analysis
Biogen
―
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-33.90%
reiterated a buy rating 2 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -33.90% per trade.
---